Post by Aniket Sanduja

Market research Consultant | Metals, Mining and Chemicals Driving 4% Growth | Manufacturing and Construction Enabling 5% Growth

Growth is visible. Profitability is where the real question begins. → US anti‑cancer drug market expected to surpass $XX billion by 2029, with immunotherapies driving a CAGR above 8% → Margin pressure from escalating R&D spend and pricing scrutiny → Uncertainty around payer reimbursements and rapid entry of biosimilars → Intensifying competition as big pharma and niche biotech chase the same indications Strategic implication: CXOs must pivot from volume‑centric plans to value‑based portfolios, leveraging real‑time market intelligence to protect margins while navigating regulatory and payer complexities. At Ken Research, we help businesses decode such market shifts through intelligence‑led strategy. Explore the full report here: https://lnkd.in/dN9Nt9_a #PharmaStrategy #MarketIntelligence #CXOInsights #HealthcareInnovation #KenResearch